Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Shares Sold by Jane Street Group LLC

Jane Street Group LLC trimmed its holdings in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 52.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 30,806 shares of the company’s stock after selling 33,479 shares during the period. Jane Street Group LLC’s holdings in Tenaya Therapeutics were worth $59,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in TNYA. Wellington Management Group LLP raised its holdings in shares of Tenaya Therapeutics by 35.6% in the 3rd quarter. Wellington Management Group LLP now owns 294,133 shares of the company’s stock worth $568,000 after purchasing an additional 77,235 shares during the period. State Street Corp raised its holdings in shares of Tenaya Therapeutics by 0.9% in the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after purchasing an additional 9,506 shares during the period. Jacobs Levy Equity Management Inc. raised its holdings in shares of Tenaya Therapeutics by 204.4% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock worth $651,000 after purchasing an additional 226,466 shares during the period. Walleye Capital LLC purchased a new position in shares of Tenaya Therapeutics in the 3rd quarter worth about $134,000. Finally, FMR LLC raised its holdings in shares of Tenaya Therapeutics by 1.9% in the 3rd quarter. FMR LLC now owns 1,345,938 shares of the company’s stock worth $2,598,000 after purchasing an additional 25,503 shares during the period. 90.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

TNYA has been the topic of a number of research reports. Leerink Partners restated an “outperform” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Canaccord Genuity Group reiterated a “buy” rating and set a $16.00 target price on shares of Tenaya Therapeutics in a report on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Tenaya Therapeutics in a report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $17.33.

Tenaya Therapeutics Stock Up 2.8 %

Shares of NASDAQ TNYA opened at $1.47 on Thursday. Tenaya Therapeutics, Inc. has a fifty-two week low of $0.99 and a fifty-two week high of $7.01. The business has a 50 day moving average price of $2.28 and a two-hundred day moving average price of $2.46. The firm has a market cap of $116.45 million, a PE ratio of -1.02 and a beta of 2.89.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.07. On average, analysts anticipate that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current year.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.